The medical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s demonstrating significant efficacy in clinical trials for addressing obesity. Unlike some current weight loss approaches, retatrutide appears to provide a greater substantial loss in body weight and enhance metabolic function, parti